CartronG, DacheuxL, SallesG, et al.Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood, 2002; 99: 754–758. DOI: 10.1182/blood.V99.3.754. PMID: 11806974.
2.
WengWK, LevyR. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 2003; 21: 3940–3947. DOI: 10.1200/JCO.2003.05.013. PMID: 12975461.
3.
ShieldsRL, NamenukAK, HongK, et al.High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J. Biol. Chem. 2001; 276: 6591–6604. DOI: 10.1074/jbc.M009483200. PMID: 11096108.
4.
IidaS, MisakaH, InoueM, et al.Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa. Clin. Cancer Res. 2006; 12: 2879–2887. DOI: 10.1158/1078-0432.CCR-05-2619. PMID: 16675584.
5.
ShieldsRL, LaiJ, KeckR, et al.Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J. Biol. Chem. 2002; 277: 26733–26740. DOI: 10.1074/jbc.M202069200. PMID: 11986321.
6.
ShinkawaT, NakamuraK, YamaneN, et al.The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. 2003; 278: 3466–73. DOI: 10.1074/jbc.M210665200. PMID: 12427744.
7.
PereiraNA, ChanKF, LinPC, SongZ. The “less-is-more” in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity. MAbs, 2018; 10(5): 693–711. DOI: 10.1080/19420862.2018.1466767. PMCID: PMC6150623. PMID: 29733746.
